Serglycin is the major cell-associated proteoglycan of hematopoietic cells. Previous work has demonstrated that serglycin may be involved in targeting some proteins to granules of cytotoxic lymphocytes, mast cells and neutrophils. We characterized the expression of serglycin in various hematologic malignancies by immunohistochemistry and ELISA. Serglycin expression was found to distinguish acute myeloid leukemia (AML) from acute lymphoblastic leukemia. In contrast to myeloperoxidase, serglycin was found to be a selective marker for immature myeloid cells, distinguishing AML from Philadelphia chromosome-negative chronic myeloproliferative disorders.
CITATION STYLE
Niemann, C. U., Kjeldsen, L., Ralfkiaer, E., Jensen, M. K., & Borregaard, N. (2007). Serglycin proteoglycan in hematologic malignancies: A marker of acute myeloid leukemia. Leukemia, 21(12), 2406–2410. https://doi.org/10.1038/sj.leu.2404975
Mendeley helps you to discover research relevant for your work.